Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
A new review found limited but growing research on the carnivore diet’s health effects. Some followers report benefits, but ...
Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...
(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as a ...
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...
Morning Overview on MSN
Parkinson’s disease tied to early metabolic changes
Parkinson’s disease may begin reshaping the body’s chemistry years before the first tremor or stiffness appears. A growing ...
Daily Voice on MSN
New research reveals what caffeine does to your brain
For many Americans, a morning cup of coffee or tea is simply part of the daily routine. New research suggests that long-held habit may also be linked to how the brain ages over time. A large, ...
The Gabelli Multimedia Trust Inc. (GGT) preferreds (GGT.PR.E, GGT.PR.G) offer over 6% current yield and trade below par. Both preferreds carry an A3 Moody's rating, low leverage (32%), and strong ...
Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results